TY - JOUR
T1 - Comparison of rubella seroepidemiology in 17 countries
T2 - Progress towards international disease control targets
AU - Nardone, Anthony
AU - Tischer, Annedore
AU - Andrews, Nick
AU - Backhouse, Jo
AU - Theeten, Heidi
AU - Gatcheva, Nina
AU - Zarvou, Marios
AU - Kriz, Bohumir
AU - Pebody, Richard G.
AU - Bartha, Kalman
AU - O'Flanagan, Darina
AU - Cohen, Dani
AU - Duks, Arnis
AU - Griskevicius, Algirdas
AU - Mossong, Joel
AU - Barbara, Christopher
AU - Pistol, Adrianna
AU - Slačiková, Margareta
AU - Prosenc, Katarina
AU - Johansen, Kari
AU - Miller, Elizabeth
PY - 2008/2
Y1 - 2008/2
N2 - Objective: To standardize serological surveillance to compare rubella susceptibility in Australia and 16 European countries, and measure progress towards international disease-control targets. Methods: Between 1996 and 2004, representative serum banks were established in 17 countries by collecting residual sera or community sampling. Serum banks were tested in each country and assay results were standardized. With a questionnaire, we collected information on current and past rubella vaccination programmes in each country. The percentage of seronegative (< 4 IU/ml) children (2-14 years of age) was used to evaluate rubella susceptibility, and countries were classified by seronegativity as group I (< 5%), group II (5-10%) or group III (> 10%). The proportion of women of childbearing age without rubella protection (≤ 10 IU/ml) was calculated and compared with WHO targets of < 5%. Findings: Only Romania had no rubella immunization programme at the time of the survey; the remaining countries had a two-dose childhood schedule using the measles, mumps and rubella (MMR) vaccine. The percentage of susceptible children defined five countries as group I, seven as group II and four as group III. Women of childbearing age without rubella protection were < 5% in only five countries. Conclusion: Despite the low reported incidence in many countries, strengthening the coverage of the routine two-dose of MMR vaccine among children is needed, especially in group III countries. Catch-up campaigns in older age groups and selective targeting of older females are needed in many countries to ensure necessary levels of protective immunity among women of childbearing age.
AB - Objective: To standardize serological surveillance to compare rubella susceptibility in Australia and 16 European countries, and measure progress towards international disease-control targets. Methods: Between 1996 and 2004, representative serum banks were established in 17 countries by collecting residual sera or community sampling. Serum banks were tested in each country and assay results were standardized. With a questionnaire, we collected information on current and past rubella vaccination programmes in each country. The percentage of seronegative (< 4 IU/ml) children (2-14 years of age) was used to evaluate rubella susceptibility, and countries were classified by seronegativity as group I (< 5%), group II (5-10%) or group III (> 10%). The proportion of women of childbearing age without rubella protection (≤ 10 IU/ml) was calculated and compared with WHO targets of < 5%. Findings: Only Romania had no rubella immunization programme at the time of the survey; the remaining countries had a two-dose childhood schedule using the measles, mumps and rubella (MMR) vaccine. The percentage of susceptible children defined five countries as group I, seven as group II and four as group III. Women of childbearing age without rubella protection were < 5% in only five countries. Conclusion: Despite the low reported incidence in many countries, strengthening the coverage of the routine two-dose of MMR vaccine among children is needed, especially in group III countries. Catch-up campaigns in older age groups and selective targeting of older females are needed in many countries to ensure necessary levels of protective immunity among women of childbearing age.
UR - http://www.scopus.com/inward/record.url?scp=38949148975&partnerID=8YFLogxK
U2 - 10.2471/BLT.07.042010
DO - 10.2471/BLT.07.042010
M3 - מאמר
AN - SCOPUS:38949148975
VL - 86
SP - 118
EP - 125
JO - Bulletin of the World Health Organization
JF - Bulletin of the World Health Organization
SN - 0042-9686
IS - 2
ER -